Artane

Basal Ganglia Diseases, Extrapyramidal symptoms caused by dibenzoxazepines, Extrapyramidal symptoms caused by thioxanthenes + 5 more
Treatment
11 FDA approvals
9 Active Studies for Artane

What is Artane

TrihexyphenidylThe Generic name of this drug
Treatment SummaryTrihexyphenidyl is a medication used to treat Parkinson's disease and other movement disorders caused by certain medications. It was first approved by the FDA in 1949, but it is no longer used as a first-line treatment due to its potential side effects. It has been largely replaced by drugs like Levodopa.
Trihexyphenidyl Hydrochlorideis the brand name
image of different drug pills on a surface
Artane Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Trihexyphenidyl Hydrochloride
Trihexyphenidyl
1987
71

Approved as Treatment by the FDA

Trihexyphenidyl, also known as Trihexyphenidyl Hydrochloride, is approved by the FDA for 11 uses which include Idiopathic Parkinson's Disease and Extrapyramidal disorder .
Idiopathic Parkinson's Disease
Extrapyramidal disorder
Helps manage Extrapyramidal disorder
arteriosclerotic Parkinsonism
Parkinson Disease
Extrapyramidal symptoms caused by thioxanthenes
Helps manage Extrapyramidal symptoms caused by thioxanthenes
Extrapyramidal symptoms caused by dibenzoxazepines
Helps manage Extrapyramidal symptoms caused by dibenzoxazepines
phenothiazine
Helps manage Extrapyramidal symptoms caused by phenothiazines
Basal Ganglia Diseases
Helps manage Extrapyramidal disorder
Butyrophenones
Helps manage Extrapyramidal symptoms caused by butyrophenones
Parkinsonism post encephalitic
Arteriosclerosis

Effectiveness

How Artane Affects PatientsTrihexyphenidyl is a medicine used to treat Parkinson's disease and other side effects from other drugs. It does not need to be taken every day, and is generally safe to use at high doses. However, people using this drug should have their eyes checked regularly and be warned of the potential risk of lack of sweat and overheating.
How Artane works in the bodyTrihexyphenidyl is a drug that helps treat symptoms of Parkinson’s disease and other movement disorders. It works by blocking a certain type of chemical messenger, called acetylcholine, in the brain and muscles. It is thought to also help increase dopamine levels in the brain, which is beneficial for movement control. The exact way it works is not yet known.

When to interrupt dosage

The suggested measure of Artane is contingent upon the diagnosed state, including phenothiazine, Extrapyramidal reactions caused by dibenzoxazepines and Butyrophenones. The amount of dosage fluctuates, in relation to the administration technique (e.g. Tablet or Tablet - Oral) shown in the following table.
Condition
Dosage
Administration
Basal Ganglia Diseases
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Extrapyramidal symptoms caused by dibenzoxazepines
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Extrapyramidal symptoms caused by thioxanthenes
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Arteriosclerosis
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Butyrophenones
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
phenothiazine
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Parkinson Disease
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral
Parkinsonism post encephalitic
, 2.0 mg/mL, 5.0 mg, 2.0 mg, 0.4 mg/mL
, Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Syrup, Syrup - Oral, Elixir, Elixir - Oral

Warnings

Artane Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Trihexyphenidyl may interact with Pulse Frequency
There are 20 known major drug interactions with Artane.
Common Artane Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Aclidinium.
Cimetropium
Major
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cimetropium.
Eluxadoline
Major
The risk or severity of constipation can be increased when Trihexyphenidyl is combined with Eluxadoline.
Glycopyrronium
Major
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glycopyrronium.
Ipratropium
Major
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ipratropium.
Artane Toxicity & Overdose RiskOverdosing on trihexyphenidyl can cause dry mouth, no sweating, dilated pupils, nausea, vomiting, rapid heartbeat, high fever, decreased digestion, difficulty urinating, rash, confusion, restlessness, poor coordination, paranoia, psychosis, delirium, and hallucinations. If left untreated, it can lead to respiratory failure, circulatory failure, and death. Treatment includes providing supportive care and airway maintenance, as well as potentially using a drug called physostigmine.
image of a doctor in a lab doing drug, clinical research

Artane Novel Uses: Which Conditions Have a Clinical Trial Featuring Artane?

Currently, 8 active clinical trials are being conducted to explore the potential of Artane to reduce Extrapyramidal symptoms caused by thioxanthenes, Post-Encephalitic Parkinsonism and Extrapyramidal symptomatology caused by dibenzoxazepines.
Condition
Clinical Trials
Trial Phases
Arteriosclerosis
1 Actively Recruiting
Not Applicable
Parkinsonism post encephalitic
0 Actively Recruiting
Extrapyramidal symptoms caused by dibenzoxazepines
0 Actively Recruiting
Butyrophenones
0 Actively Recruiting
Basal Ganglia Diseases
0 Actively Recruiting
Extrapyramidal symptoms caused by thioxanthenes
0 Actively Recruiting
phenothiazine
0 Actively Recruiting
Parkinson Disease
8 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable

Artane Reviews: What are patients saying about Artane?

5Patient Review
6/21/2014
Artane for Extrapyramidal Reaction
I feel really good when I take this medication. It's a great high and I get really horny, too. The orgasms are also way better.
5Patient Review
10/25/2017
Artane for Parkinson's Disease
This treatment was good and it helped me.
4.3Patient Review
2/16/2011
Artane for Parkinson Symptoms
I developed tardive dyskenesia from taking abilify, and was prescribed 10mg of Artane. This dosage was far too high for me, and caused extreme short-term memory loss for a few hours after taking it. After several doses, I started to feel nauseous, but drinking orange juice with pulp would help alleviate this. I now only take a quarter of a 5mg pill every now and then, which has kept my symptoms at bay. The Danbury brand is also much better than Qualitest in terms of not upsetting my stomach.
4.3Patient Review
12/21/2013
Artane for Extrapyramidal Reaction
I have oral mandibular dystonia, which this medication has helped me somewhat with.
4Patient Review
10/25/2014
Artane for Extrapyramidal Reaction
It increases my appetite and sex drive, as well as making me have to use the restroom more frequently.
3.7Patient Review
9/21/2010
Artane for Extrapyramidal Reaction
3.3Patient Review
7/2/2010
Artane for Parkinson's Disease
2.3Patient Review
4/24/2022
Artane for Extrapyramidal Reaction
This medication did its job in that I only had one faint myoclonic jerk while on it. However, I found it to be very cognitively impairing and memory- affecting. All in all, I would not recommend this medication because of these serious side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about artane

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Artane cause anxiety?

"You may experience serious side effects from taking Artane, including fast or irregular heartbeats, anxiety, hallucinations, confusion, agitation, hyperactivity, or loss of consciousness. Seizures and eye pain are also possible. If you experience any of these symptoms, seek medical attention immediately."

Answered by AI

What is the drug Artane used for?

"Artane is an antispasmodic drug that is used to treat symptoms of Parkinson's disease, such as stiffness, tremors, spasms, and poor muscle control. Artane can also be used to prevent these symptoms when they are caused by certain drugs."

Answered by AI

Why is Artane used in schizophrenia?

"Anticholinergic drugs are used in psychiatric practice to counteract the side effect of EPS secondary to antipsychotic drugs. Trihexyphenidyl (Benzhexol), commonly known as 'Artane', is the most widely used anticholinergic drug in Zambia."

Answered by AI

How does Artane make you feel?

"tiredness, lightheadedness, constipation, flushing, nausea, nervousness, blurred vision, or dry mouth may occur. These effects generally improve as your body becomes accustomed to the medication. If any of these effects persist or worsen, contact your doctor or pharmacist."

Answered by AI

Clinical Trials for Artane

Image of London Health Sciences Center.London ,Ontario in London, Canada.

Wearable Technology for Parkinson's Disease

18+
All Sexes
London, Canada
This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day. The project will use a smartwatch and mobile app (KinesiaU) to continuously track movement, allowing for more responsive and personalized treatment compared to traditional monitoring methods. In this pilot randomized controlled trial, 32 participants will be assigned to either: A control group receiving standard care, or A wearable device group receiving standard care plus using the smartwatch. Outcomes will be assessed over a 4-week period, focusing on changes in motor function, quality of life, and self-management. The study will also examine feasibility, adherence, and data quality. If successful, this trial will provide critical evidence for integrating wearable devices into routine clinical care for PD, paving the way for larger efficacy trials and more patient-centered care strategies.
Waitlist Available
Has No Placebo
London Health Sciences Center.London ,Ontario (+1 Sites)
Image of University of Florida, Norman Fixel Institute for Neurological Diseases in Gainesville, United States.

Deep Brain Stimulation for Parkinson's Disease

45 - 85
All Sexes
Gainesville, FL
Nearly one-million people in North America are now living with Parkinson's disease (PD), and that number is projected to rise to nearly 1.2 million by 2030. With advancements in neuromodulatory technologies, increasingly more of these individuals elect to undergo deep brain stimulation (DBS) surgery in order to control symptoms of the disease, including refractory tremor, medication-induced dyskinesias, and PD-associated dystonia. The two most common DBS neural targets for controlling these symptoms are the globus pallidus internal segment (GPi) and the subthalamic nucleus (STN). Recent meta-analyses have shown relative equivalence between these two sites at controlling core PD symptoms. To date, there is not conclusive evidence regarding the potential impact of DBS to GPi or STN on laryngeal-mediated functions of voice, swallowing, and cough, and consequently no guidance on whether these outcomes should be considered when selecting DBS target. Therefore, the goal of this project is to determine the impact of DBS neural target (STN versus GPi), lead location within the target, laterality, and stimulation settings on voice, swallow and cough function in people with PD. The larynx is an important player in each of these functions, and our central hypothesis is that spread of stimulation to corticobulbar fibers in the genu of the internal capsule have deleterious effects on laryngeal motor control, resulting in voice, swallow, and cough dysfunction. We have identified three specific aims for this application: 1.) To compare laryngeal function during volitional voice tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 2.) To compare laryngeal function during volitional and induced cough tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 3.) To compare airway safety associated with laryngeal onset, degree, and duration of maximum closure during swallowing, pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. These hypotheses were developed based on compelling published and unpublished preliminary data. We will accomplish these aims by enrolling people with PD who are being considered for DBS surgery. We will measure physiologic, functional, and quality of life parameters of voice, swallow and cough pre- and post-surgically. The realization of the proposed aims is significant because it will address a substantial gap in our understanding of DBS outcomes related to communication and airway protection, which are important in terms of morbidity, mortality, and quality of life for patients with PD. The translational potential to provide additional guidance to DBS surgical teams regarding whether voice, swallow or cough functions should be considered with selecting DBS target and/or laterality is high. Ultimately, the project fits squarely within the overarching goal of the research team to deliver the best possible care to people with PD.
Recruiting
Has No Placebo
University of Florida, Norman Fixel Institute for Neurological DiseasesKaren Hegland, Ph.D.
Image of Integrated Health and Movement Science Laboratory, Saint Louis University in St. Louis, United States.

Community Walking Program for Parkinson's Disease

30 - 85
All Sexes
St. Louis, MO
This study will investigate the feasibility of a 6-month community walking program for people with Parkinson's disease (PD) and their care partners in greater Saint Louis, Missouri region. The walking program will consist of weekly, organized walking groups at the Missouri Botanical Gardens. Participants in the program will use Nordic walking poles during the walks. The walking group(s) will meet once per week and will be supervised by walking group leaders from Saint Louis University. Participants will be given a smart watch to wear that will help step counts will be tracked in real-time. The program is designed to get people with Parkinson's disease out of their homes, cultivate a culture of connection with others with Parkinson's disease, and to be collectively accountable for a common goal toward increasing their physical and social engagement in their communities.
Recruiting
Has No Placebo
Integrated Health and Movement Science Laboratory, Saint Louis University (+1 Sites)
Have you considered Artane clinical trials? We made a collection of clinical trials featuring Artane, we think they might fit your search criteria.Go to Trials
Image of University of Rochester Medical Center for Health + Technology in Rochester, United States.

Palliative Care for Parkinson's Disease

18+
All Sexes
Rochester, NY
The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.
Recruiting
Quick Reply
Has No Placebo
University of Rochester Medical Center for Health + TechnologyBenzi Kluger, MD
Image of Cleveland Clinic in Cleveland, United States.

Physical Therapy + Medication for Parkinson's Disease

18 - 90
All Sexes
Cleveland, OH
Gait and balance problems are a significant source of disability in patients with Parkinson disease. Physical therapy remains one of the main treatments. On the other hand some medications, such as methyphenidate and atomoxetine, have been tried with promising results. The outcomes in gait and balance in Parkinson disease after a combination of physical therapy and the medications mentioned above have not been explored yet. The investigators want to evaluate whether the addition of medication, either low dose of methylphenidate or atomoxetine, to physical therapy will achieve improvement in gait and balance in Parkinson disease more than physical therapy alone. The investigators propose a pilot, single center, rater blind, prospective randomized trial. 2-arm-parallel group, intention-to-treat analysis.
Phase < 1
Recruiting
Cleveland ClinicHubert Fernandez
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security